FDA Prohibits Manufacture of FDA-Regulated Drugs from Ranbaxy's Mohali, India, Plant and Issues Import Alert
The US Food and Drug Administration today issued an import alert under which US officials may detain at the US border drug products manufactured at Ranbaxy Laboratories, Ltd.’s facility in Mohali, India.